HRP20201426T1 - Postupci i pripravci za moduliranje ekspresije apolipoproteina (a) - Google Patents
Postupci i pripravci za moduliranje ekspresije apolipoproteina (a) Download PDFInfo
- Publication number
- HRP20201426T1 HRP20201426T1 HRP20201426TT HRP20201426T HRP20201426T1 HR P20201426 T1 HRP20201426 T1 HR P20201426T1 HR P20201426T T HRP20201426T T HR P20201426TT HR P20201426 T HRP20201426 T HR P20201426T HR P20201426 T1 HRP20201426 T1 HR P20201426T1
- Authority
- HR
- Croatia
- Prior art keywords
- wing segment
- modified oligonucleotide
- compound according
- linked nucleosides
- modified
- Prior art date
Links
- 102100040214 Apolipoprotein(a) Human genes 0.000 title claims 4
- 108010012927 Apoprotein(a) Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 19
- 239000002777 nucleoside Substances 0.000 claims 19
- 108091034117 Oligonucleotide Proteins 0.000 claims 16
- 125000003835 nucleoside group Chemical group 0.000 claims 14
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 5
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 4
- 101710115418 Apolipoprotein(a) Proteins 0.000 claims 3
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (16)
1. Spoj za smanjenje ekspresije apo(a), naznačen time, što sadrži modificirani oligonukleotid koji se sastoji od 15 do 30 povezanih nukleozida i koji ima nukleobaznu sekvencu koja sadrži dio od najmanje 15 uzastopnih nukleobaza komplementarnih s dijelom jednake duljine nukleobaza od 3900 do 3923 iz SEQ ID NO: 1, te pri čemu je nukleobazna sekvenca modificiranog oligonukleotida najmanje 80% komplementarna sa SEQ ID NO: 1.
2. Spoj prema patentnom zahtjevu 1, naznačen time, što se modificirani oligonukleotid sastoji od 18 do 24, 19 do 22, 15 do 25, 16 ili 20 povezanih nukleozida.
3. Spoj prema patentnom zahtjevu 1, naznačen time, što modificirani oligonukleotid obuhvaća nukleobaznu sekvencu koja sadrži dio od najmanje 16, najmanje 18, najmanje 19, ili najmanje 20 uzastopnih nukleobaza komplementarnih s dijelom jednake duljine iz SEQ ID NO: 1.
4. Spoj prema bilo kojem prethodnom patentnom zahtjevu, naznačen time, što je nukleobazna sekvenca modificiranog oligonukleotida najmanje 85%, najmanje 90%, najmanje 95%, ili 100% komplementarna sa SEQ ID NO: 1.
5. Spoj prema bilo kojem prethodnom patentnom zahtjevu, naznačen time, što nukleobazna sekvenca modificiranog oligonukleotida obuhvaća najmanje 15, najmanje 16, najmanje 17, najmanje 18, najmanje 19, ili 20 uzastopnih nukleobaza nukleobazne sekvence iz SEQ ID NO: 58.
6. Spoj prema bilo kojem prethodnom patentnom zahtjevu, naznačen time, što se modificirani oligonukleotid sastoji od 18 do 24 povezanih nukleozida, i pri čemu nukleobazna sekvenca sadrži najmanje 18 uzastopnih nukleobaza nukleobazne sekvence iz SEQ ID NO: 58.
7. Spoj prema bilo kojem prethodnom patentnom zahtjevu, naznačen time, što:
(i) modificirani oligonukleotid je jednostrane strukture,
(ii) najmanje jedna međunukleozidna veza je modificirana međunukleozidna veza, po izboru pri čemu je najmanje jedna međunukleozidna veza fosforotioatna međunukleozidna veza,
(iii) modificirani oligonukleotid obuhvaća najmanje jedan modificirani šećer, po izboru pri čemu: (a) najmanje jedan modificirani šećer je biciklički šećer, po izboru ograničeni etil ili šećer koji sadrži 4'-(CH2)n-O-2' most, pri čemu n je 1 ili 2, ili (b) najmanje jedan modificirani šećer koji sadrži 2'-O-metoksietil, ili je 3'-fluoro-HNA, i/ili
(iv) najmanje jedan nukleozid sadrži modificiranu nukleobazu, po izboru pri čemu je modificirana nukleobaza 5-metilcitozin.
8. Spoj prema bilo kojem prethodnom patentnom zahtjevu, naznačen time, što modificirani oligonukleotid obuhvaća:
segment procjepa koji se sastoji od povezanih deoksinukleozida;
5' krilni segment koji se sastoji od povezanih nukleozida;
3' krilni segment koji se sastoji od povezanih nukleozida;
pri čemu je segment procjepa smješten između 5' krilnog segmenta i 3' krilnog segmenta i pri čemu svaki nukleozid iz svakog krilnog segmenta sadrži modificirani šećer.
9. Spoj prema patentnom zahtjevu 8, naznačen time, što se modificirani oligonukleotid sastoji od 20 povezanih nukleozida i sadrži:
segment procjepa koji se sastoji od deset povezanih deoksinukleozida;
5' krilni segment koji se sastoji od pet povezanih nukleozida;
3' krilni segment koji se sastoji od pet povezanih nukleozida;
pri čemu je segment procjepa smješten između 5' krilnog segmenta i 3' krilnog segmenta, pri čemu svaki nukleozid iz svakog krilnog segmenta sadrži 2'-O-metoksietil šećer, pri čemu svaka međunukleozidna veza je fosforotioatna veza i pri čemu svaki citozinski ostatak je 5-metilcitozin.
10. Spoj prema bilo kojem prethodnom patentnom zahtjevu, naznačen time, što se modificirani oligonukleotid sastoji od 20 povezanih nukleozida i ima nukleobaznu sekvencu koja sadrži najmanje 15 uzastopnih nukleobaza nukleobazne sekvence iz SEQ ID NO: 58, pri čemu modificirani oligonukleotid obuhvaća:
segment procjepa koji se sastoji od deset povezanih deoksinukleozida;
5' krilni segment koji se sastoji od pet povezanih nukleozida;
3' krilni segment koji se sastoji od pet povezanih nukleozida;
pri čemu je segment procjepa smješten između 5' krilnog segmenta i 3' krilnog segmenta, pri čemu svaki nukleozid svakog krilnog segmenta sadrži 2'-O-metoksietil šećer, pri čemu svaka međunukleozidna veza je fosforotioatna veza i pri čemu svaki citozinski ostatak je 5-metilcitozin.
11. Spoj koji sadrži modificirani oligonukleotid koji se sastoji od 20 povezanih nukleozida i koji ima nukleobaznu sekvencu iz SEQ ID NO: 58, naznačen time, što modificirani oligonukleotid obuhvaća:
segment procjepa koji se sastoji od deset povezanih deoksinukleozida;
5' krilni segment koji se sastoji od pet povezanih nukleozida;
3' krilni segment koji se sastoji od pet povezanih nukleozida;
pri čemu je segment procjepa smješten između 5' krilnog segmenta i 3' krilnog segmenta, pri čemu svaki nukleozid svakog krilnog segmenta sadrži 2'-O-metoksietil šećer, pri čemu svaka međunukleozidna veza je fosforotioatna veza i pri čemu svaki citozinski ostatak je 5-metilcitozin.
12. Spoj prema bilo kojem od patentnih zahtjeva 8-11, naznačen time, što je modificirani oligonukleotid jednostrane strukture.
13. Spoj prema bilo kojem prethodnom patentnom zahtjevu, naznačen time, što je spoj konjugirani antisens-spoj.
14. Pripravak, naznačen time, što sadrži spoj prema bilo kojem prethodnom patentnom zahtjevu, pri čemu po izboru spoj je sol, te farmaceutski prihvatljiv nosač ili razrjeđivač.
15. Spoj prema bilo kojem od patentnih zahtjeva 1-13 ili pripravak prema zahtjevu 14, naznačen time, što je za upotrebu u terapiji.
16. Spoj ili pripravak za uporabu u skladu s patentnim zahtjevom 15, naznačen time, što terapija je liječenje, sprečavanje ili usporavanje napredovanja bolesti povezane s povišenim apo(a) i/ili povišenim Lp(a), po izboru pri čemu je bolest upalna, kardiovaskularna ili metabolička bolest, takav poremećaj ili takvo stanje.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651539P | 2012-05-24 | 2012-05-24 | |
| EP13793955.9A EP2855500B1 (en) | 2012-05-24 | 2013-05-23 | Methods and compositions for modulating apolipoprotein(a) expression |
| PCT/US2013/042532 WO2013177468A2 (en) | 2012-05-24 | 2013-05-23 | Methods and compositions for modulating apolipoprotein(a) expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201426T1 true HRP20201426T1 (hr) | 2020-11-27 |
Family
ID=49624530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201426TT HRP20201426T1 (hr) | 2012-05-24 | 2020-09-07 | Postupci i pripravci za moduliranje ekspresije apolipoproteina (a) |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20150152411A1 (hr) |
| EP (3) | EP2855500B1 (hr) |
| JP (3) | JP6082809B2 (hr) |
| KR (4) | KR20170142997A (hr) |
| CN (2) | CN108359668A (hr) |
| AU (4) | AU2013266196A1 (hr) |
| CA (2) | CA3185392A1 (hr) |
| CY (1) | CY1123367T1 (hr) |
| DK (1) | DK2855500T3 (hr) |
| ES (1) | ES2820548T3 (hr) |
| HK (1) | HK1208870A1 (hr) |
| HR (1) | HRP20201426T1 (hr) |
| HU (1) | HUE051680T2 (hr) |
| IL (2) | IL235746B (hr) |
| LT (1) | LT2855500T (hr) |
| MX (1) | MX360639B (hr) |
| NZ (1) | NZ631071A (hr) |
| PL (1) | PL2855500T3 (hr) |
| PT (1) | PT2855500T (hr) |
| RU (2) | RU2624028C2 (hr) |
| SI (1) | SI2855500T1 (hr) |
| WO (1) | WO2013177468A2 (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160002624A1 (en) | 2012-05-17 | 2016-01-07 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide compositions |
| US9593333B2 (en) * | 2013-02-14 | 2017-03-14 | Ionis Pharmaceuticals, Inc. | Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations |
| JP6995478B2 (ja) | 2013-05-01 | 2022-01-14 | アイオーニス ファーマシューティカルズ， インコーポレーテッド | Ｈｂｖおよびｔｔｒ発現を調節するための組成物および方法 |
| BR112016024850B1 (pt) | 2014-05-01 | 2021-07-06 | Ionis Pharmaceuticals, Inc | compostos e composições para modulação da expressão de angptl3 e seus usos |
| WO2015179693A1 (en) | 2014-05-22 | 2015-11-26 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| SG10202001856WA (en) * | 2015-04-16 | 2020-04-29 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression |
| JOP20210043A1 (ar) * | 2015-10-01 | 2017-06-16 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| PE20181180A1 (es) | 2015-11-06 | 2018-07-20 | Ionis Pharmaceuticals Inc | MODULAR LA EXPRESION DE APOLIPOPROTEINA (a) |
| US20190046555A1 (en) | 2015-11-06 | 2019-02-14 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds for use in therapy |
| CN109661233A (zh) | 2016-10-06 | 2019-04-19 | Ionis 制药公司 | 缀合低聚化合物的方法 |
| US20180193270A1 (en) | 2016-11-29 | 2018-07-12 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| CN113286885A (zh) | 2018-11-09 | 2021-08-20 | 诺华股份有限公司 | 用靶向apo(a)的经缀合的反义化合物降低心血管事件的风险的方法 |
| JP7394137B2 (ja) | 2018-12-21 | 2023-12-07 | アイオニス・ファーマシューティカルズ・インコーポレイテッド | Ｈｓｄ１７ｂ１３発現のモジュレータ |
| WO2023041079A1 (zh) * | 2021-09-18 | 2023-03-23 | 上海金中锘美生物医药科技有限公司 | Lpa抑制剂及其用途 |
| TW202345865A (zh) * | 2022-01-24 | 2023-12-01 | 大陸商上海舶望製藥有限公司 | 抑制LPA(Apo(a))蛋白表達的組合物和方法 |
| CN114703184B (zh) * | 2022-03-11 | 2024-06-18 | 厦门甘宝利生物医药有限公司 | Lpa抑制剂及其用途 |
| CN117568313B (zh) * | 2024-01-15 | 2024-04-26 | 上海贝斯昂科生物科技有限公司 | 基因编辑组合物及其用途 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
| US2699508A (en) | 1951-12-21 | 1955-01-11 | Selectronics Inc | Method of mounting and construction of mounting for low frequency piezoelectric crystals |
| RU95114435A (ru) | 1992-12-14 | 1997-05-20 | Ханивелл Инк. (Us) | Система с бесщеточным двигателем постоянного тока |
| US5599706A (en) | 1994-09-23 | 1997-02-04 | Stinchcomb; Dan T. | Ribozymes targeted to apo(a) mRNA |
| US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
| US7875733B2 (en) | 2003-09-18 | 2011-01-25 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| EP1557424A1 (en) | 1997-09-12 | 2005-07-27 | Exiqon A/S | Bi-cyclic nucleoside, nucleotide and oligonucleoide analogues |
| WO1999035241A1 (en) * | 1998-01-08 | 1999-07-15 | Aventis Pharmaceuticals Products Inc. | Transgenic rabbit that expresses a functional human lipoprotein (a) |
| NZ514348A (en) | 1999-05-04 | 2004-05-28 | Exiqon As | L-ribo-LNA analogues |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| CA2452458A1 (en) | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| US7259150B2 (en) * | 2001-08-07 | 2007-08-21 | Isis Pharmaceuticals, Inc. | Modulation of apolipoprotein (a) expression |
| US7227014B2 (en) * | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
| WO2003014397A1 (en) | 2001-08-09 | 2003-02-20 | Biomedlab Corporation | Probe for detection of enteric virus detection kit and method for enteric virus with the same |
| JP2004121152A (ja) * | 2002-10-04 | 2004-04-22 | Japan Science & Technology Agency | リポタンパク（ａ）とアテローム硬化症との関係 |
| CA2504694C (en) | 2002-11-05 | 2013-10-01 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| AU2003290596B2 (en) | 2002-11-05 | 2011-05-12 | Isis Pharmaceuticals, Inc. | Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| CA2511012C (en) | 2002-12-20 | 2018-02-27 | Applera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
| AU2003224132A1 (en) * | 2003-04-24 | 2004-11-19 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| EP1661905B9 (en) | 2003-08-28 | 2012-12-19 | IMANISHI, Takeshi | Novel artificial nucleic acids of n-o bond crosslinkage type |
| US7662389B2 (en) * | 2003-12-17 | 2010-02-16 | Alcon, Inc. | Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
| US20050244851A1 (en) * | 2004-01-13 | 2005-11-03 | Affymetrix, Inc. | Methods of analysis of alternative splicing in human |
| CN101151035A (zh) * | 2004-12-02 | 2008-03-26 | Isis制药公司 | 用于治疗炎性肠病的治疗性反义寡核苷酸组合物 |
| DK1984381T3 (da) | 2006-01-27 | 2010-11-01 | Isis Pharmaceuticals Inc | 6-modificerede bicycliske nukleinsyreanaloger |
| WO2007143315A2 (en) * | 2006-05-05 | 2007-12-13 | Isis Pharmaceutical, Inc. | Compounds and methods for modulating expression of pcsk9 |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| JP4798093B2 (ja) | 2006-08-04 | 2011-10-19 | 日産自動車株式会社 | 流体改質装置及びこれを用いた流体改質方法 |
| JP5665317B2 (ja) | 2006-10-18 | 2015-02-04 | アイシス ファーマシューティカルズ， インコーポレーテッド | アンチセンス化合物 |
| US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| WO2008098129A2 (en) * | 2007-02-07 | 2008-08-14 | Indiana University Research And Technology Corporation | Materials and methods for detecting and treating peritoneal ovarian tumor dissemination involving tissue transglutaminase |
| EP2125852B1 (en) | 2007-02-15 | 2016-04-06 | Ionis Pharmaceuticals, Inc. | 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom |
| US8278425B2 (en) | 2007-05-30 | 2012-10-02 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| DK2173760T4 (en) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocyclic bicyclic nukleinsyreanaloge |
| US8278283B2 (en) | 2007-07-05 | 2012-10-02 | Isis Pharmaceuticals, Inc. | 6-disubstituted or unsaturated bicyclic nucleic acid analogs |
| CN101619346B (zh) * | 2008-07-04 | 2014-02-19 | 上海交通大学医学院附属瑞金医院 | 人冠心病易感基因-脂蛋白a基因拷贝数变异检测方法和试剂盒 |
| EP3093351B1 (en) | 2008-07-09 | 2018-04-18 | Celera Corporation | Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof |
| JP6128732B2 (ja) * | 2008-10-03 | 2017-05-17 | クルナ・インコーポレーテッド | アポリポタンパク質−ａ１に対する天然アンチセンス転写物の抑制によるアポリポタンパク質−ａ１関連疾患の治療 |
| US9778706B2 (en) | 2012-02-24 | 2017-10-03 | Blackberry Limited | Peekable user interface on a portable electronic device |
| US20160002624A1 (en) | 2012-05-17 | 2016-01-07 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide compositions |
| US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
| JP6995478B2 (ja) * | 2013-05-01 | 2022-01-14 | アイオーニス ファーマシューティカルズ， インコーポレーテッド | Ｈｂｖおよびｔｔｒ発現を調節するための組成物および方法 |
-
2013
- 2013-05-23 EP EP13793955.9A patent/EP2855500B1/en active Active
- 2013-05-23 RU RU2014148708A patent/RU2624028C2/ru active
- 2013-05-23 CA CA3185392A patent/CA3185392A1/en active Pending
- 2013-05-23 US US14/403,557 patent/US20150152411A1/en not_active Abandoned
- 2013-05-23 PT PT137939559T patent/PT2855500T/pt unknown
- 2013-05-23 KR KR1020177035895A patent/KR20170142997A/ko active Search and Examination
- 2013-05-23 PL PL13793955T patent/PL2855500T3/pl unknown
- 2013-05-23 EP EP20180985.2A patent/EP3822352A3/en active Pending
- 2013-05-23 SI SI201331787T patent/SI2855500T1/sl unknown
- 2013-05-23 LT LTEP13793955.9T patent/LT2855500T/lt unknown
- 2013-05-23 DK DK13793955.9T patent/DK2855500T3/da active
- 2013-05-23 CN CN201810142395.7A patent/CN108359668A/zh active Pending
- 2013-05-23 MX MX2014014339A patent/MX360639B/es active IP Right Grant
- 2013-05-23 NZ NZ631071A patent/NZ631071A/en unknown
- 2013-05-23 KR KR1020217003043A patent/KR102657351B1/ko active IP Right Grant
- 2013-05-23 CA CA2874480A patent/CA2874480C/en active Active
- 2013-05-23 WO PCT/US2013/042532 patent/WO2013177468A2/en active Application Filing
- 2013-05-23 AU AU2013266196A patent/AU2013266196A1/en not_active Abandoned
- 2013-05-23 RU RU2017120536A patent/RU2748495C2/ru active
- 2013-05-23 KR KR1020197019779A patent/KR20190084354A/ko not_active IP Right Cessation
- 2013-05-23 CN CN201380025618.7A patent/CN104302654B/zh active Active
- 2013-05-23 JP JP2015514209A patent/JP6082809B2/ja active Active
- 2013-05-23 KR KR1020147031371A patent/KR101810841B1/ko active IP Right Grant
- 2013-05-23 ES ES13793955T patent/ES2820548T3/es active Active
- 2013-05-23 EP EP20212913.6A patent/EP3825403A3/en active Pending
- 2013-05-23 HU HUE13793955A patent/HUE051680T2/hu unknown
-
2014
- 2014-11-17 IL IL235746A patent/IL235746B/en active IP Right Grant
-
2015
- 2015-10-02 HK HK15109676.5A patent/HK1208870A1/xx unknown
-
2016
- 2016-10-21 US US15/331,297 patent/US9885045B2/en active Active
-
2017
- 2017-01-16 AU AU2017200277A patent/AU2017200277B2/en active Active
- 2017-01-20 JP JP2017008821A patent/JP6472820B2/ja active Active
- 2017-12-20 US US15/849,017 patent/US10472629B2/en active Active
-
2018
- 2018-09-24 AU AU2018236699A patent/AU2018236699C1/en active Active
-
2019
- 2019-01-16 IL IL264288A patent/IL264288B2/en unknown
- 2019-01-23 JP JP2019009255A patent/JP6934895B2/ja active Active
-
2020
- 2020-09-07 HR HRP20201426TT patent/HRP20201426T1/hr unknown
- 2020-09-29 CY CY20201100915T patent/CY1123367T1/el unknown
- 2020-12-02 AU AU2020281071A patent/AU2020281071A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201426T1 (hr) | Postupci i pripravci za moduliranje ekspresije apolipoproteina (a) | |
| HRP20211397T1 (hr) | Pripravci za modulaciju ekspresije ataksina 2 | |
| HRP20211051T1 (hr) | Pripravci namijenjeni moduliranju eksprimiranja tau | |
| NZ710192A (en) | Modulation of apolipoprotein ciii (apociii) expression | |
| RU2015151200A (ru) | Композиции и способы модулирования экспрессии аполипопротеина (а) | |
| HRP20210612T1 (hr) | Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk | |
| HRP20201200T1 (hr) | OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK | |
| SI2379084T1 (en) | Modulation of factor expression 11 | |
| HRP20191600T1 (hr) | Modulatori faktora b komplementa | |
| JP2013226147A5 (hr) | ||
| NL300963I9 (nl) | Een verbinding omvattende een gemodificeerd oligonucleotide met een nucleobasensequentie bestaande uit 20 gekoppelde nucleosiden volgens EP-B1-2563920 conclusie 1 (SEQ ID NO: 80), waarbij de gemodificeerde oligonucleotide omvat: een tussenruimtesegment dat bestaat uit tien gekoppelde deoxynucleosiden; een 5' vleugelsegment dat bestaat uit vijf gekoppelde nucleosiden; en een 3' vleugelsegment dat bestaat uit vijf gekoppelde nucleosiden; waarbij het tussenruimtesegment is gepositioneerd tussen het 5' vleugelsegment en het 3' vleugelsegment, waarbij elke nucleoside van elk vleugelsegment een 2'-O-methoxyethylsuiker omvat; waarbij elke cytosine van het gemodificeerde oligonucleotide een 5-methylcytosine is, en waarbij elke internucleosidekoppeling van het gemodificeerde oligonucleotide een fosforothioaatkoppeling is; en in het bijzonder inotersen; en derivaten daarvan, zoals zouten ervan, waaronder natriumzouten, zoals beschermd door EP-B1-2563920. | |
| HRP20200843T1 (hr) | Sastavi za moduliranje ekspresije c9orf72 | |
| JP2015507625A5 (hr) | ||
| RU2016129725A (ru) | Модуляция экспрессии ангиопоэтин-подобного белка 3 | |
| RU2016116849A (ru) | Композиции для модуляции экспрессии c90rf72 | |
| JP2017510271A5 (hr) | ||
| MX359548B (es) | Agentes de iarn modificados. | |
| JP2014513954A5 (hr) | ||
| FI2906696T4 (fi) | Menetelmiä c9orf72:n ilmentymisen moduloimiseksi | |
| HRP20191348T1 (hr) | Aminosteroidi za liječenje bolesti povezanih s ptp1b | |
| JP2016533717A5 (hr) | ||
| PE20181085A1 (es) | Composiciones y metodos para modular la expresion de angiotensinogeno | |
| RU2016130110A (ru) | Способы хирургической обработки путем резания и сшивания скобками | |
| SG10201903290YA (en) | Modified double-stranded rna agents | |
| RU2012114198A (ru) | Модуляция экспрессии гентингтина |